
Denali Therapeutics (DNLI) Stock Forecast & Price Target
Denali Therapeutics (DNLI) Analyst Ratings
Bulls say
Denali Therapeutics is viewed favorably because its TfR-based BBB transport platform can deliver both systemic and CNS therapies with potentially lower development risk, while addressing high-unmet-need neurodegenerative and rare disease targets. Commercially, AVLAYAH is validating the platform with 3Q26 net product revenue of $17.8M, a beat versus expectations, 4Q26 guidance of $30.0M to $32.0M, and access expanding to more than 70% of U.S. commercial lives plus 20 state Medicaid programs. Its balance sheet and pipeline also support the thesis, with about $1.0B in cash after the PRV sale and several catalysts expected in 1H27 and 2027 across DNL593, DNL628, DNL952, DNL921, DNL151, and zafinofusp alfa.
Bears say
Denali Therapeutics is vulnerable to regulatory uncertainty because its reliance on accelerated review paths does not eliminate the risk that regulators will demand additional data, change approval standards, or require longer studies. Such outcomes could delay commercialization and weaken the company’s competitive position if approved products fail to secure labels with the necessary features to gain traction in the market. Financially, the company will likely need to access capital markets to fund ongoing development, and any difficulty raising funds could constrain cash resources and slow or impair completion of its programs.
This aggregate rating is based on analysts' research of Denali Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Denali Therapeutics (DNLI) Analyst Forecast & Price Prediction
Start investing in Denali Therapeutics (DNLI)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Denali Therapeutics (DNLI) Forecast
Denali Therapeutics (DNLI) Analyst Forecast & Price Prediction
Start investing in Denali Therapeutics (DNLI)
Order type
Buy in
Order amount
Est. shares
0 shares